Cost-effectiveness of pembrolizumab for first-line treatment in patients with persistent, recurrent, or metastatic cervical cancer in the United States by [email protected] | Oct 30, 2023
Use of Real-World Data in Cost-Effectiveness Analysis of Sequential Biologic Treatment for Rheumatoid Arthritis by [email protected] | Oct 30, 2023
Health care resource utilization (HCRU) and costs in patients with biliary tract cancer (BTC) treated with systemic therapy in the United States (US) by [email protected] | Oct 20, 2023
Medical and non-medical reasons for discontinuation of anti-TNF agents in patients with UC in real-world setting: A systematic review by [email protected] | Oct 20, 2023
